Literature DB >> 26669822

Effect of postoperative use of diclofenac on pharyngocutaneous fistula development after primary total laryngopharyngectomy: Results of a single-center retrospective study.

Thomas Parzefall1, Axel Wolf1, Shelly Czeiger2, Klemens Frei1, Michael Formanek3, Boban M Erovic1.   

Abstract

BACKGROUND: Primary total laryngopharyngectomy is the treatment of choice in many cases of locally advanced hypopharyngeal and laryngeal cancer. Development of pharyngocutaneous fistulae is the most common postoperative complication. A recent Danish study showed significantly increased rates of anastomosal leakage after colorectal resection in patients receiving diclofenac treatment.
METHODS: We retrospectively analyzed 67 patients after primary total laryngopharyngectomy to determine whether diclofenac increases the risk for development of pharyngocutaneous fistula analogously to leakage in the colorectal area.
RESULTS: The fistula rate in the total study population (n = 67) was 19.4%. In the group receiving diclofenac postoperatively (n = 31), the fistula rate was 25.8%. In the patient group not receiving diclofenac (n = 36), the fistula rate was 13.9% (p = .219).
CONCLUSION: Our results suggest that cyclooxygenase-2 (COX-2) selective nonsteroidal anti-inflammatory drugs (NSAIDs) should be administered with caution after laryngopharyngectomy. Additional studies on larger cohorts are required to further evaluate our findings.
© 2015 Wiley Periodicals, Inc. Head Neck 38: E1515-E1520, 2016. © 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  diclofenac; laryngopharyngectomy; nonsteroidal anti-inflammatory drug (NSAID); pharyngocutaneous fistula; primary laryngectomy

Mesh:

Substances:

Year:  2015        PMID: 26669822     DOI: 10.1002/hed.24271

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  1 in total

1.  Bacterial colonization of Montgomery salivary bypass tubes after hypopharyngeal reconstruction in head and neck cancer patients.

Authors:  Stefan Grasl; Stefan Janik; Matthaeus Christoph Grasl; Bernhard Parschalk; Boban M Erovic; Georg Haymerle
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-12-17       Impact factor: 2.503

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.